Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.45 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998732 | 0.87 | TOP2A (0.46) | TOP2ATOP2BKCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL5001842 | 0.86 | TOP2A (0.46) | TOP2ATOP2BKCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL7009585 | 0.86 | TOP2A (0.57) | TOP2ATOP2BKCNH2KDM4ECYP1A2 | |
| SCHEMBL4998765 | 0.84 | KCNH2 (0.52) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| SCHEMBL4998742 | 0.83 | KCNH2 (0.46) | TOP2ATOP2BKCNH2KDM4EGSK3B | |
| SCHEMBL7493758 | 0.83 | TMEM97 (0.42) | TOP2ATOP2BGSK3B | |
| SCHEMBL4996678 | 0.80 | KDM4E (0.49) | TOP2ATOP2BKCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL4998901 | 0.79 | TOP2A (0.46) | TOP2ATOP2BKCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL7007516 | 0.79 | KDM4E (0.52) | TOP2ATOP2BKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL7009271 | 0.78 | TOP2A (0.72) | TOP2ATOP2BKCNH2GSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371868-B2 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20070225506-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE AND ITS INTERMEDIATE, AS WELL AS SALT OF 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE, ITS HYDRATE AND COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| US-6482835-B2 | SUCH AS (R)-1-CYCLOPROPYL-8-DIFLUOROMETHOXY-7-(1-METHYL-2,3-DIHYDRO-1H-5-ISOINDOLYL)-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXYL IC ACID METHANESULFONATE; CHEMICAL INTERMEDIATES; BACTERICIDES; CATALYSIS | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6337399-B1 | CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| EP-1031569-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6025370-A | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0882725-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | BRD7, IMPDH1, DDT | TOP2A 206/4885TOP2B 92/4885KCNH2 979/4885 |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | KCNQ2, CYP4X1, HAAO | TOP2A 596/4885TOP2B 343/4885KCNH2 52/4885 |
| US-20070225506-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE AND ITS INTERMEDIATE, AS WELL AS SALT OF 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE, ITS HYDRATE AND COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | DHX15, HAAO, DHX35 | TOP2A 664/4885TOP2B 327/4885KCNH2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.